Skip to main content

Krystal Biotech

Krystal Biotech Inc is an American commercial-stage biotechnology company developing topical and redeliverable gene therapies for rare genetic diseases. The company's proprietary STAR-001 platform utilizes engineered HSV-1 viral vectors to deliver functional genes directly to skin and tissue cells. Its FDA-approved flagship product, Vyjuvek, is a topical gene therapy designed to treat dystrophic epidermolysis bullosa by restoring functional type VII collagen. Principal revenue is derived from direct commercial sales of Vyjuvek in North America, alongside government research grants and licensing agreements for international drug commercialization. Krystal Biotech holds a pioneering commercial position as the first company to gain regulatory approval for a topical redeliverable gene therapy. Headquartered in Pittsburgh, Pennsylvania, the company's common stock is publicly listed and traded on the Nasdaq Global Market under the ticker KRYS.

9 of the funds FundTelligence covers report a position in Krystal Biotech.

Legal name
Krystal Biotech Inc
Sector
Health Care
Country
United States
Funds holding it
9
Exposure themes
Gene Therapy, Genetic Medicine, Precision Medicine & Genomics

Funds holding Krystal Biotech

Showing the 8 largest of 9 funds holding it.

Loading...